Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases

被引：0
|
作者：
Crino, Lucio [1 ]
Ahn, Myung-Ju [2 ]
De Marinis, Filippo [3 ]
Groen, H. J. M. [4 ,5 ]
Wakelee, Heather A. [6 ]
Hida, Toyoaki [7 ]
Mok, Tony [8 ]
Shaw, Alice [9 ]
Felip, Enriqueta [10 ]
Nishio, Makoto [11 ]
Scagliotti, Giorgio V. V. [12 ]
Branle, Fabrice [13 ]
Emeremni, Chetachi [14 ]
Sutradhar, Santosh [15 ]
Quadrigli, Massimiliano [13 ]
Zhang, Jie [15 ]
Spigel, David [16 ]
机构：
[1] Perugia Hosp, Perugia, Italy
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[4] Univ Groningen, Groningen, Netherlands
[5] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[6] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[7] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Vall DHebron Univ Hosp, Barcelona, Spain
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Univ Turin, Turin, Italy
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharma AG, E Hanover, NJ USA
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ALK Inhibitor; brain metastases; Patient-reported outcomes; Ceritinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI31.13
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [21] Time to Progression and Post-Progression Survival in ALK plus Ceritinib-Treated NSCLC
    Liu, Geoffrey
    Zhang, Jie
    Zhou, Zheng-Yi
    Li, Junlong
    Cai, Xiaopeng
    Signorovitch, James
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S237
  • [22] Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain Metastases
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S377
  • [23] Phase 2 Study of Ceritinib in Patients with ALK plus NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
    Horinouchi, H.
    Maemondo, M.
    Hida, T.
    Takeda, M.
    Hotta, K.
    Hirai, F.
    Kim, Y.
    Matsumoto, S.
    Mitsudomi, T.
    Seto, T.
    Moizumi, S.
    Tokushige, K.
    Hatano, B.
    Nishio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1951 - S1952
  • [24] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
    Park, K.
    Tan, D.
    Ahn, M. -J.
    Yu, C. -J.
    Tsai, C. -M.
    Hida, T.
    Nishio, M.
    Branle, F.
    Emeremni, C.
    Mok, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
  • [25] The Efficacy and Safety of Ceritinib in the Treatment of ALK plus NSCLC: A Systematic Review and Meta-Analysis
    Luo, P.
    Fan, J.
    Xia, Z.
    Zhang, X.
    Chen, Y.
    Qian, R.
    Liu, S.
    You, D.
    Zhang, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [26] Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials
    Gettinger, Scott
    Kim, Dong-Wan
    Tiseo, Marcello
    Langer, Corey
    Ahn, Myung-Ju
    Shaw, Alice
    Huber, Rudolf
    Hochmair, Maximilian
    Kim, Sang-We
    Bazhenova, Lyudmila
    Gold, Kathryn
    Ou, Sai-Hong
    West, Howard
    Reichmann, William
    Haney, Jeff
    Clackson, Tim
    Haluska, Frank
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S273 - S274
  • [27] Ceritinib in Anaplastic Lymphoma Kinase (ALK) plus NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
    Shaw, A.
    Kim, D.
    Solomon, B.
    Felip, E.
    Riely, G.
    Schuler, M.
    Tan, D.
    Chow, L.
    Camidge, D. R.
    Urban, P.
    Ortmann, C.
    Malet, I.
    Mehra, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1896 - S1897
  • [28] Ensartinib rapidly relieves symptoms in ALK-positive patients with brain metastases
    Xu, Hongyan
    Chen, Tingting
    Zheng, Yan
    Fang, Wenzheng
    ASIAN JOURNAL OF SURGERY, 2024, 47 (09) : 3947 - 3949
  • [29] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
    De Castro, Gilberto, Jr.
    Tan, Daniel Shao-Weng
    Crino, Lucio
    Wu, Yi Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximilian
    Cortot, Alexis
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario Garcia
    Branle, Fabrice
    Sen, Paramita
    Mcculloch, Tracey
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S7 - S7
  • [30] Advanced NSCLC patients: Comparison between those with and without brain metastases
    Techasatian, Tanwimon
    Saichaemchan, Siriwimon
    ANNALS OF ONCOLOGY, 2023, 34 : S1451 - S1451
12345